EGFR and chronic obstructive pulmonary disease: Therefore, inhibiting EGFR tyrosine kinase activity may be beneficial to the treatment of hypersecretory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis.